Abbott Laboratories vs. Corcept Therapeutics Inc.
Abbott Laboratories (ABT) comes out ahead, leading on 7 of 9 compared factors.
Size & Scale
| ABT | CORT | |
|---|---|---|
| Market Cap | $175.27 billion | $12.55 billion |
| Revenue (TTM) | $46.59 billion | $741.17 million |
| Net Income (TTM) | $5.42 billion | $106.11 million |
ABT leads on 3 of 3 size & scale factors.
Valuation
| ABT | CORT | |
|---|---|---|
| P/E Ratio | 32.78 | 133.45 |
| Price / Book | 3.39 | 19.86 |
| Price / Sales | 3.76 | 16.93 |
ABT leads on 3 of 3 valuation factors.
Profitability
| ABT | CORT | |
|---|---|---|
| Net Margin | 11.65% | 14.32% |
| Return on Equity | 10.48% | 16.79% |
CORT leads on 2 of 2 profitability factors.
Dividend
| ABT | CORT | |
|---|---|---|
| Dividend Yield | 2.49% | — |
| Payout Ratio | 81.55 | — |
ABT and CORT split the dividend factors evenly.
Risk & Sentiment
| ABT | CORT | |
|---|---|---|
| Short Interest | 0.57% | 16.06% |
ABT leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, CORT overview, CORT financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.